---

---

approved   entities : Sanofi   

save search

---

FDA Rejects Abeona’s Gene Therapy, Approves ImmunityBio’s Bladder Cancer Treatment
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| 0.0% | O: 0.3% H: 0.0% C: 0.0%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| 0.53% | O: 0.89% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| 0.0% | O: 0.47% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| 0.0% | O: 1.7% H: 0.0% C: 0.0%
fda bladder cancer treatment

---

Busy Weekend Sees Tumor-Agnostic Win for Enhertu, Another Rejection for Supernus
Published: 2024-04-08 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| 0.01% | O: 2.24% H: 0.0% C: -0.8%
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -4.27% | O: 0.96% H: 1.17% C: 0.16%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -2.24% | O: -0.48% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -3.71% | O: 0.09% H: 0.16% C: -0.7%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -1.39% | O: 0.84% H: 0.0% C: 0.0%
for

---

FDA Approves Vanda Schizophrenia Drug for Bipolar I Disorder
Published: 2024-04-03 (Crawled : 13:30) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -4.02% | O: -0.29% H: 1.34% C: -0.64%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -5.46% | O: 0.02% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -4.42% | O: 0.11% H: 0.37% C: -0.77%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -2.99% | O: 0.69% H: 0.0% C: 0.0%
fda drug schizophrenia

---

AstraZeneca Kicks Off April With New PNH Approval
Published: 2024-04-02 (Crawled : 13:30) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -6.38% | O: -1.09% H: 0.13% C: -1.39%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -5.49% | O: -0.77% H: 0.8% C: 0.74%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -4.48% | O: -0.18% H: 0.47% C: 0.12%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -5.11% | O: -1.14% H: 0.02% C: -1.06%
approval astrazeneca

---

FDA Approves Treatments for Anemia in Chronic Kidney Disease, Hepatitis
Published: 2024-03-29 (Crawled : 19:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| Email alert Add to watchlist
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| Email alert Add to watchlist
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| Email alert Add to watchlist
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| Email alert Add to watchlist
fda hepatitis kidney anemia

---

FDA Approves New Treatments for Two Rare Diseases
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -2.4% | O: 0.84% H: 1.48% C: 1.29%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -4.18% | O: 0.3% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -3.05% | O: 1.48% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -5.95% | O: 1.06% H: 0.0% C: 0.0%
fda rare

---

COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: Glo...
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -5.95% | O: 1.06% H: 0.0% C: 0.0%
copd potential market

---

COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: GlobalData
Published: 2024-03-27 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -5.95% | O: 1.06% H: 0.0% C: 0.0%
copd potential market

---

Regeneron Hit With Two CRLs, J&J’s PAH Treatment Approved
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -4.02% | O: 0.35% H: 0.35% C: -1.34%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -4.14% | O: 0.04% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -3.17% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -3.73% | O: 0.42% H: 0.0% C: 0.0%
approved treatment

---

Italfarmaco’s Duvyzat, Idorsia’s Tryvio Earn FDA Nod for DMD, Hypertension
Published: 2024-03-22 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -2.65% | O: -1.58% H: 0.0% C: 0.0%
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -4.81% | O: 0.35% H: 0.99% C: -1.17%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -4.12% | O: 0.02% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -4.4% | O: -0.43% H: 0.41% C: -0.85%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -2.5% | O: 1.47% H: 0.23% C: -0.19%
fda hypertension

---

FDA Approves Takeda’s Iclusig for Type of Leukemia, Idorsia’s Hypertension Drug
Published: 2024-03-21 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -2.29% | O: 0.14% H: 0.24% C: 0.24%
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -3.96% | O: 0.0% H: 1.6% C: 0.89%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -4.15% | O: -0.03% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -4.94% | O: -0.56% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -2.21% | O: 0.3% H: 0.0% C: 0.0%
fda drug iclusig hypertension

---

FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -1.02% | O: 0.33% H: 0.13% C: -1.51%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -5.77% | O: 0.2% H: 0.08% C: -1.14%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -5.59% | O: 1.71% H: 0.36% C: -2.52%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -4.43% | O: -0.81% H: 0.0% C: 0.0%
fda rare first disease therapy

---

Madrigal’s Rezdiffra, BMS’s Breyanzi Lead Week of Landmark FDA Approvals
Published: 2024-03-15 (Crawled : 15:00) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -2.62% | O: -0.62% H: 0.59% C: -1.01%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -7.26% | O: -1.58% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -10.81% | O: -5.53% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -4.45% | O: -0.02% H: 0.0% C: 0.0%
fda breyanzi week

---

FDA Decisions: Wegovy Approved for CV Indication; Viatris and Mapi’s MS Drug ...
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -0.63% | O: 0.0% H: 2.38% C: 1.12%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -6.18% | O: 0.43% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -11.36% | O: 0.26% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -3.71% | O: 0.57% H: 0.0% C: 0.0%
fda drug wegovy approved

---

FDA Decisions: Wegovy Approved for CV Indication; Viatris and Mapi’s MS Drug Rejected
Published: 2024-03-11 (Crawled : 14:30) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| -0.63% | O: 0.0% H: 2.38% C: 1.12%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -6.18% | O: 0.43% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -11.36% | O: 0.26% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -3.71% | O: 0.57% H: 0.0% C: 0.0%
fda drug wegovy approved

---

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -3.71% | O: 0.57% H: 0.0% C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K |

Health Technology

| -7.09% | O: 0.23% H: 0.9% C: -0.68%
praluent fda children genetic cholesterol approval treat injection

---

FDA Decisions: BeiGene Secures Record Fifth Oncology Approval for Brukinsa
Published: 2024-03-08 (Crawled : 18:00) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| 1.25% | O: 0.98% H: 3.17% C: 0.9%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -6.82% | O: -0.68% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -10.85% | O: 0.58% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -3.79% | O: -0.08% H: 0.0% C: 0.0%
fda brukinsa approval

---

FDA Decisions: BeiGene Secures Record Fifth Oncology Approval for Brukinsa; Opdivo Approved for B...
Published: 2024-03-08 (Crawled : 17:00) - biospace.com/
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| 1.25% | O: 0.98% H: 3.17% C: 0.9%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -6.82% | O: -0.68% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -10.85% | O: 0.58% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -3.79% | O: -0.08% H: 0.0% C: 0.0%
fda opdivo approved approval

---

Decision Tracker: FDA Decisions: Amgen’s Bone-Preserving Blockbuster Picks Up Two New Challengers
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -1.01% | O: 0.0% H: 0.8% C: 0.8%
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| 10.27% | O: -0.15% H: 3.43% C: 3.2%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -7.18% | O: -0.67% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -11.08% | O: -1.65% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -2.68% | O: -0.45% H: 0.0% C: 0.0%
fda

---

FDA Decisions: J&J’s Rybrevant Becomes First Front-Line Treatment for Type of NSCLC
Published: 2024-03-04 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -1.9% | O: -0.9% H: 0.0% C: 0.0%
PRGO | $30.49 1.43% 0.0% 1.1M |

Health Technology

| 14.17% | O: 0.65% H: 1.13% C: -1.02%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -7.85% | O: -0.42% H: 0.0% C: 0.0%
ABT | News | $107.59 0.49% -0.09% 3.8M |

Health Technology

| -9.63% | O: 0.03% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -2.33% | O: -0.8% H: 0.0% C: 0.0%
fda first treatment rybrevant

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---